The legal battle over Mifepristone’s reach across state lines took a complicated turn Tuesday, when a federal judge refused to immediately shut down mail-order prescriptions for the controversial abortion drug — while simultaneously telling Louisiana it might ultimately win its fight.
Louisiana Attorney General Liz Murrill had walked into court seeking swift action. She wanted U.S. Food and Drug Administration rules — put in place in 2023 — suspended while her challenge to them winds through the judicial system. She walked out empty-handed on the injunction, but carrying ammunition for the road ahead.
U.S. District Judge David Joseph, a Trump appointee sitting in Lafayette, chose a different path entirely. Rather than rule immediately on the merits, he froze the case in place — granting the federal government’s request for a pause while making unmistakably clear that the freeze has a clock ticking on it.
Joseph trained his eyes squarely on an ongoing FDA study of mifepristone and told the agency it has six months to report back on that review’s progress. His message to federal regulators was direct: move slowly at your own risk.
“Should the agency fail to complete its review and make any necessary revisions” to the rules “within a reasonable time frame, the Court’s analysis — and the weight accorded to these factors — will inevitably change,” Joseph wrote in his opinion.
More striking still was what else Joseph put on paper. He wrote that he believes the plaintiffs are “likely to succeed on the merits” — a declaration that sent a signal to both the court of law and the court of public opinion that Louisiana’s case carries genuine legal weight.
Murrill seized on those words. In a statement following the ruling, she announced plans to take the fight to an appeals court, framing the outcome as validation rather than defeat. The judge, she noted, “concluded that Louisiana suffers irreparable harm every day” the current regulations remain in place.
The core of Louisiana’s argument is that allowing Mifepristone to be prescribed by telehealth and shipped through the mail directly undermines the state’s authority to restrict abortion within its own borders.
That argument has found traction in conservative legal circles, with Republican officials in multiple other states pursuing parallel challenges in their own federal districts.
Murrill has not limited her effort to the courtroom. She is also pursuing criminal cases against individual physicians — one practicing in California, another in New York — whom she accuses of mailing abortion pills to Louisiana patients. Both states have declined to hand the doctors over to face charges in Louisiana.
Among those standing with Murrill as a plaintiff is a Louisiana woman who alleges her boyfriend pressured her into taking Mifepristone obtained from a California physician.
That account helped shape a central theme of the plaintiffs’ legal strategy: that without mandatory in-person requirements surrounding the abortion pill, coercive relationships become a hidden pipeline for forced abortions.
Some advocates who work with domestic abuse survivors pushed back on that characterization, arguing telehealth access can itself be a critical lifeline for women in dangerous situations.
On the other side of the courtroom’s aftermath, abortion rights supporters were quick to pump the brakes on any celebration. Planned Parenthood Federation of America President and CEO Alexis McGill Johnson issued a pointed statement: “From the courts to the Trump administration to state legislatures across the country, mifepristone and abortion access are very much still under attack.”
The drug, typically taken alongside a second medication called misoprostol, has become the central front in the post-Roe abortion landscape since the Supreme Court’s 2022 decision eliminated the constitutional right to abortion.
Two years later, the nation’s highest court declined to block Mifepristone mail prescriptions in a separate lawsuit — though that ruling turned on a procedural finding that the anti-abortion doctors who filed it lacked legal standing to do so.
The numbers tell the story of how dramatically the terrain has shifted. Research shows that by the end of 2024, one in four abortions in the United States was accessed through telehealth — a fivefold jump in just two years.
A subsequent study found that by 2025, women in abortion-restricted states were more likely to obtain pills through the mail than to travel across state lines to a clinic.
Eight states have responded by passing laws designed to protect telehealth providers who prescribe and ship abortion pills into restricted territory.
A federal judge in Hawaii ruled last year that the FDA itself violated the law by imposing certain restrictions on mifepristone — the same drug also used in miscarriage management. And the Trump administration drew sharp criticism from anti-abortion groups after approving an additional generic version of the pill.
Tuesday’s ruling resolved nothing permanently. It set a timer.
